EG18333A - Process for preparing ifosphamide lyophilisate - Google Patents

Process for preparing ifosphamide lyophilisate

Info

Publication number
EG18333A
EG18333A EG61687A EG61687A EG18333A EG 18333 A EG18333 A EG 18333A EG 61687 A EG61687 A EG 61687A EG 61687 A EG61687 A EG 61687A EG 18333 A EG18333 A EG 18333A
Authority
EG
Egypt
Prior art keywords
ifosphamide
lyophilisate
preparing
ifosfamide
weight
Prior art date
Application number
EG61687A
Other languages
English (en)
Original Assignee
Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Ag filed Critical Pharma Ag
Application granted granted Critical
Publication of EG18333A publication Critical patent/EG18333A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Control Of El Displays (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Amplifiers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EG61687A 1986-10-31 1987-10-28 Process for preparing ifosphamide lyophilisate EG18333A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3637089 1986-10-31

Publications (1)

Publication Number Publication Date
EG18333A true EG18333A (en) 1993-12-30

Family

ID=6312873

Family Applications (1)

Application Number Title Priority Date Filing Date
EG61687A EG18333A (en) 1986-10-31 1987-10-28 Process for preparing ifosphamide lyophilisate

Country Status (25)

Country Link
EP (1) EP0265812B1 (lv)
JP (1) JPS63159319A (lv)
KR (1) KR900003491B1 (lv)
AT (1) ATE55250T1 (lv)
AU (1) AU598602B2 (lv)
CA (1) CA1314231C (lv)
DD (1) DD262582A5 (lv)
DE (1) DE3764235D1 (lv)
DK (1) DK169308B1 (lv)
EG (1) EG18333A (lv)
ES (1) ES2017982B3 (lv)
FI (1) FI87140C (lv)
GE (1) GEP19971025B (lv)
GR (1) GR3000708T3 (lv)
HU (1) HU197987B (lv)
IL (1) IL84312A (lv)
IN (1) IN168119B (lv)
LV (1) LV10051B (lv)
MX (1) MX8958A (lv)
NO (1) NO873860L (lv)
PT (1) PT86032B (lv)
RU (1) RU1836079C (lv)
UA (1) UA11075A (lv)
YU (1) YU197387A (lv)
ZA (1) ZA878183B (lv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE65402T1 (de) * 1988-03-19 1991-08-15 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
WO1995007083A1 (en) * 1993-09-10 1995-03-16 F.H. Faulding & Co. Limited Ifosfamide lyophilisate composition
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
WO1999044604A1 (en) * 1998-03-03 1999-09-10 Shionogi & Co., Ltd. Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate
JP2006508917A (ja) * 2002-09-05 2006-03-16 ブハラット セルムズ アンド ヴァクシンズ リミテッド メスナを有する、オキサザホスホリンの液体安定性組成物
DE60332385D1 (de) * 2002-12-02 2010-06-10 Bharat Serums & Vaccines Ltd Ifosfamid-zusammensetzungen zur parenteralen verabreichung und verfahren für ihre herstellung
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP2412359A1 (en) * 2006-09-29 2012-02-01 Infa S.A. Packaging system for pharmaceutical compositions and kit for intravenous administration
WO2016087001A1 (en) * 2014-12-04 2016-06-09 Huawei Technologies Co., Ltd. Load allocation in a data communication network

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732340A (en) * 1966-07-11 1973-05-08 Asta Werke Ag Chem Fab N',o-propylene phosphoric acid ester diamides
DE2750207A1 (de) * 1977-05-09 1978-11-16 Walton J Smith Gefriergetrocknete zusammensetzungen, insbesondere gefriergetrocknete pharmazeutische praeparate und verfahren zu deren herstellung
DE3279834D1 (en) * 1981-12-31 1989-08-31 Asta Pharma Ag 4-sulfido-oxaza phosphorines and their use in the treatment of cancer, and in immunosuppression
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide

Also Published As

Publication number Publication date
EP0265812B1 (de) 1990-08-08
KR900003491B1 (ko) 1990-05-21
YU197387A (en) 1988-12-31
DE3764235D1 (de) 1990-09-13
AU598602B2 (en) 1990-06-28
NO873860L (no) 1988-05-02
EP0265812A1 (de) 1988-05-04
GR3000708T3 (en) 1991-10-10
FI87140B (fi) 1992-08-31
GEP19971025B (en) 1997-04-06
FI874727A0 (fi) 1987-10-27
DK169308B1 (da) 1994-10-10
MX8958A (es) 1993-12-01
IL84312A (en) 1991-11-21
JPH0543684B2 (lv) 1993-07-02
ZA878183B (en) 1988-05-02
FI87140C (fi) 1992-12-10
UA11075A (uk) 1996-12-25
LV10051B (en) 1995-06-20
ATE55250T1 (de) 1990-08-15
ES2017982B3 (es) 1991-03-16
HUT44932A (en) 1988-05-30
JPS63159319A (ja) 1988-07-02
CA1314231C (en) 1993-03-09
DD262582A5 (de) 1988-12-07
LV10051A (lv) 1994-05-10
RU1836079C (ru) 1993-08-23
IN168119B (lv) 1991-02-09
DK569687D0 (da) 1987-10-30
FI874727A (fi) 1988-05-01
DK569687A (da) 1988-05-01
IL84312A0 (en) 1988-03-31
PT86032B (pt) 1990-08-31
HU197987B (en) 1989-07-28
KR880004814A (ko) 1988-06-27
NO873860D0 (no) 1987-09-15
PT86032A (de) 1987-11-01
AU8052987A (en) 1988-05-05

Similar Documents

Publication Publication Date Title
EP0348808A3 (de) Neue Arzneimittelformulierung sowie Verfahren zu deren Herstellung
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
EP0498471A3 (en) Liposomes comprising a guanidino aminoglycoside
GR3007251T3 (lv)
NO900528D0 (no) Anthelmintika, fremgangsmaate for fremstilling derav, og preparat med et innhold derav.
LU90949I2 (fr) Esters aminoalcohol d'acide thienylcarboxyliques leurs produits quaternaires leur préparation et l'utilisation de ces composés
GR3002377T3 (en) Ifosfamide-mesna-lyophilized composition and process to prepare it
HUT44438A (en) Composition comprising l-dopa
AU1331588A (en) Method for treatment of alcohol abuse
EG18333A (en) Process for preparing ifosphamide lyophilisate
HUT49808A (en) Process for producing retarde pharmaceutical compositions containing aselastine
PT84552A (en) Process for the preparation of a insecticidal composition containing bacterial spores and process for producing the reported spores
ZA882449B (en) Dihydropyridinamides,a process for their preparation,and their use in medicaments
ZA894667B (en) Process for the preparation of 2,6-dichlorodiphenyl-amino-acetic derivatives
GR3003638T3 (lv)
HUT46212A (en) Process for production of antibacterial liofilized compounds
IL83495A0 (en) Oxirane pseudooligosaccharides,a process for their preparation,and pharmaceutical preparations containing them
EP0415564A3 (en) Improvement of excretion of nonprotein nitrogen into the intestine by prostanoic acid derivaties
HUT46693A (en) Process for producing dioxabicyclo/3,3,0/oktanon-oxim-ethers and pharmaceutical compositions containing them as active components
IL83606A0 (en) Derivatives of 2,2-dimethyl-cyclopropanecarboxylic acid,their preparation and their use as insecticides and acaricides
IT1186793B (it) Frazione ottenuta da listeria monocytogenes avente attivita' terapeutica,procedimento per la sua preparazione e composioni farmaceutiche che la contengono